Gilead shares dip after $3.15 billion Tubulis deal adds ADC asset, as multiple acquisitions reshape oncology and autoimmune pipeline outlook.
Importance Rank:
1
Gilead shares dip after $3.15 billion Tubulis deal adds ADC asset, as multiple acquisitions reshape oncology and autoimmune pipeline outlook.
Copyright © Louis Velazquez. All Rights Reserved.